Biofrontera Inc. (BFRIW) Aandelenanalyse

Bedrijfsoverzicht

Biofrontera Inc. is a biopharmaceutical enterprise dedicated to the commercialization of pharmaceutical products designed for the treatment of dermatological conditions within the United States market. The company specifically markets Ameluz, BF-RhodoLED, the RhodoLED XL lamp series, and RhodoLED Lamps, which are utilized for the management of actinic keratosis. Although the specific sector and industry classifications are not explicitly defined in the available data, the operational focus is clearly situated within the biotechnology and medical devices landscape, a space characterized by high research and development costs and specialized regulatory pathways. The organization employs a workforce of 84 individuals, reflecting a lean operational structure typical of clinical-stage or commercializing biopharma firms. Given that the market capitalization and price-to-sales ratio are not reported, the company's scale is primarily reflected through its annual revenue of $41.70 million, which indicates a niche but commercially active position in the dermatological treatment sector.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $41.70 million, while posting a net income of -$10,536,000 and an EBITDA of -$11,210,000. The substantial gap between the positive revenue figure and the significant net loss reveals a cost structure where operating expenses, likely dominated by research, development, and sales & marketing costs, far exceed current earnings generation. Free cash flow stands at -$2,362,000, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating surplus liquidity from its core business activities. Despite the net losses, the gross margin is robust at 73.7%, suggesting high efficiency in production or significant pricing power for its pharmaceutical and device portfolios. The operating margin is reported at 26.7%, which is positive and indicates that operating expenses are being managed effectively relative to sales, although the bottom line remains negative. However, the profit margin is negative at -25.3%, confirming that the non-operating costs or the specific accounting treatment of the net loss outweighs the operating profitability. On the balance sheet, the company holds $6.40 million in cash against $6.16 million in debt, resulting in a debt-to-equity ratio of 58.79. The current ratio is 1.52, which indicates a healthy level of short-term liquidity as the company possesses 1.52 times the assets required to cover its current liabilities. Return on Equity is -141.3% and return on assets is -28.0%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than returns.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E ratio are not applicable (N/A), which implies that without positive earnings, traditional earnings-based valuation metrics cannot be calculated or do not reflect the current market expectation of future earnings trajectory. The price-to-book ratio is 0.05, indicating that the market values the company's equity at only 5% of its book value, a significant discount that often reflects the risks associated with negative earnings or the intangible nature of biopharma assets. Since the price-to-sales ratio and EV/EBITDA are not reported, alternative valuation metrics that rely on profitability or enterprise value multiples are unavailable for comparison with peers. The stock has traded within a 52-week range with a high of $0.06 and a low of $0.05, meaning the current valuation sits within a very narrow band relative to this historical range. The beta is 0.64, which signifies that the stock's price volatility is historically lower than the broader market, suggesting that the share price moves less drastically than the overall market index. This low beta is consistent with the stock trading at a low price point and potentially lower trading volume typical of smaller cap biotech entities.

Growth & Income

Revenue growth year-over-year is 36.2%, demonstrating a strong expansion in top-line sales driven by the commercialization of its dermatological treatments. Earnings growth is not applicable due to the company's ongoing net losses, which means earnings are not yet growing in a positive trajectory relative to revenue. As the company does not pay a dividend, there is no dividend yield or payout ratio to evaluate for sustainability. Instead of distributing income to shareholders, the company retains all earnings to fund its operations, research, and potential future product development. The overall growth and income profile is characterized by robust revenue expansion in the absence of current profitability, relying on retained capital rather than dividend payments to support its strategic initiatives.